Sarepta Therapeutics (SRPT) Stock Jumps Ahead of Elevidys Data Release

Sarepta Therapeutics shares surged roughly 5% in after-hours trading following an announcement of upcoming 3-year data for its Duchenne gene therapy Elevidys. The stock had closed down 3% at $21.13 before rebounding to $22.20 post-market.

The biotech firm will present topline results from its EMBARK Phase 3 study on January 26, with the timing strategically set one hour before market open. This release comes as Elevidys faces heightened scrutiny - the FDA recently imposed its strongest safety warning and restricted use to ambulatory patients following liver failure deaths in non-ambulatory cases.

Despite fourth-quarter headwinds from flu season, Elevidys generated $898.7 million of Sarepta's preliminary $1.86 billion 2025 revenue. Monday's data drop could prove pivotal for demonstrating whether early treatment benefits persist and for addressing lingering safety concerns that have shadowed the therapy's commercial potential.